RxDoctor Payments Data

Cynthia Wagnon, MD

Internal Medicine · Delhi, LANPI 1225009053

Payments from drug & device makers

$364in general payments, 2019–2025

Across 14 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$155
  • Boehringer Ingelheim$55
  • Abbott$31
  • Bayer$21
  • AstraZeneca$21
  • Pfizer$21
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364 in reported general payments places this provider in the 45th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,487
Medicare patients
23
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide204$219,878
JardianceEmpagliflozin90$75,050
EliquisApixaban119$70,676
JanuviaSitagliptin Phosphate70$46,656
MyrbetriqMirabegron80$44,100
Divalproex Sodium ErDivalproex Sodium174$17,009
RybelsusSemaglutide13$14,184
TradjentaLinagliptin25$12,196
XareltoRivaroxaban12$11,005
CreonLipase/Protease/Amylase14$9,353
LokelmaSodium Zirconium Cyclosilicate14$8,318
LinzessLinaclotide13$7,477
Breo ElliptaFluticasone/Vilanterol18$6,740
Levothyroxine Sodium751$6,532
Potassium Chloride275$6,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$13$234,062217 claims
Boehringer IngelheimJardiance, Tradjenta$55$87,247115 claims
PfizerEliquis$21$70,676119 claims
Astellas Pharma US IncMyrbetriq$155$44,10080 claims
AbbVieCreon, Linzess, Synthroid$16$18,77286 claims
AstraZenecaLokelma$21$8,31814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Delhi

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →